A phase I, open label, clinical study to assess the safety and immunogenicity of indigenously developed liquid (DTwP-HepB-IPV-Hib) hexavalent combination vaccine in healthy toddlers aged 16-24 months

• Egile Nagusiak: Hitt Sharma (Egilea), Sanjay Lalwani (Egilea), Sameer Parekh (Egilea), Pramod Pujari (Egilea), Sunil Shewale (Egilea), Sonali Palkar (Egilea), Neeta Hanumante (Egilea), Shilpa Gokhale (Egilea), Jaganathan Ks (Egilea), Rakesh Kumar (Egilea), Inderjit Sharma (Egilea), Sunil Gairola (Egilea)
• Formatua: Liburua
• Argitaratua: Taylor & Francis Group, 2022-11-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

This first in human study was designed as an open label clinical trial to assess the safety and immunogenicity of SIIPL DTwP-HepB-IPV-Hib (Hexavalent) combination vaccine in healthy toddlers, aged 16-24 months. A total of 24 healthy toddlers were administered a 0.5 ml single dose of SIIPL DTwP-HepB-...